| 24.62 -0.33 (-1.32%) | 04-19 13:24 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 33.59  |
1-year : | 36.47 |
| Resists | First : | 28.76 |
Second : | 31.22 |
| Pivot price | 27.68 |
|||
| Supports | First : | 24.78 |
Second : | 20.61 |
| MAs | MA(5) : | 25.55 |
MA(20) : | 28.19 |
| MA(100) : | 33.38 |
MA(250) : | 27.47  |
|
| MACD | MACD : | -1.5 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 2 |
D(3) : | 2.4 |
| RSI | RSI(14): 30.5 |
|||
| 52-week | High : | 44.31 | Low : | 12.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BBIO ] has closed above bottom band by 11.1%. Bollinger Bands are 1.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.7 - 25.88 | 25.88 - 26.02 |
| Low: | 24.33 - 24.58 | 24.58 - 24.76 |
| Close: | 24.65 - 24.97 | 24.97 - 25.22 |
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Tue, 16 Apr 2024
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Update - MarketBeat
Sun, 07 Apr 2024
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical ... - GlobeNewswire
Fri, 22 Mar 2024
BridgeBio Pharma: Assessing Acoramidis' Market Opportunity (NASDAQ:BBIO) - Seeking Alpha
Wed, 06 Mar 2024
Latham & Watkins Advises on BridgeBio's Public Offering of Common Stock - Latham & Watkins LLP
Tue, 05 Mar 2024
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock - Yahoo Finance
Tue, 05 Mar 2024
Deals report: BridgeBio taps Bayer as EU partner - BioCentury
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 184 (M) |
| Held by Insiders | 1.1302e+008 (%) |
| Held by Institutions | 5.3 (%) |
| Shares Short | 13,640 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.9295e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 123.9 % |
| Return on Equity (ttm) | -64.1 % |
| Qtrly Rev. Growth | 9.3e+006 % |
| Gross Profit (p.s.) | -6.51 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -528 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.2 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.33 |
| Dividend | 0 |
| Forward Dividend | 1.428e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|